Lexaria Bioscience (LEXX) Competitors $1.02 +0.05 (+5.66%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. ANL, IFRX, HOWL, DRRX, DTIL, IZTC, IMA, CLNN, PDSB, and ICCCShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Adlai Nortye (ANL), InflaRx (IFRX), Werewolf Therapeutics (HOWL), DURECT (DRRX), Precision BioSciences (DTIL), Invizyne Technologies (IZTC), ImageneBio (IMA), Clene (CLNN), PDS Biotechnology (PDSB), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors Adlai Nortye InflaRx Werewolf Therapeutics DURECT Precision BioSciences Invizyne Technologies ImageneBio Clene PDS Biotechnology ImmuCell Lexaria Bioscience (NASDAQ:LEXX) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Which has more risk and volatility, LEXX or ANL? Lexaria Bioscience has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500. Does the media refer more to LEXX or ANL? In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 1 articles in the media. Adlai Nortye's average media sentiment score of 0.47 beat Lexaria Bioscience's score of -1.00 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Negative Adlai Nortye Neutral Do analysts prefer LEXX or ANL? Lexaria Bioscience currently has a consensus price target of $4.00, suggesting a potential upside of 292.16%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 411.36%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, LEXX or ANL? Lexaria Bioscience has higher earnings, but lower revenue than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K43.37-$5.80M-$0.67-1.52Adlai Nortye$5M12.99-$51.87MN/AN/A Is LEXX or ANL more profitable? Adlai Nortye has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Adlai Nortye's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% Adlai Nortye N/A N/A N/A Do institutionals and insiders hold more shares of LEXX or ANL? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAdlai Nortye beats Lexaria Bioscience on 7 of the 13 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.95M$3.17B$5.79B$9.92BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.5221.2175.7326.67Price / Sales43.37477.57556.54122.11Price / CashN/A45.1137.1158.92Price / Book2.139.9611.296.07Net Income-$5.80M-$53.47M$3.29B$266.51M7 Day Performance15.87%2.37%0.62%-0.04%1 Month Performance15.91%8.28%6.94%3.84%1 Year Performance-69.09%13.65%57.33%23.68% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience3.0328 of 5 stars$1.02+5.7%$4.00+292.2%-71.9%$19.95M$460K-1.527Negative NewsShort Interest ↑Gap UpANLAdlai Nortye1.4075 of 5 stars$1.73+3.0%$9.00+421.7%-37.1%$61.82MN/A0.00127News CoverageShort Interest ↑Gap UpIFRXInflaRx3.1467 of 5 stars$0.92+0.8%$6.60+616.7%+1.0%$61.33M$162.83K-1.1560News CoveragePositive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeHOWLWerewolf Therapeutics2.6037 of 5 stars$1.37+3.8%$8.00+483.9%-34.1%$60.36M$1.88M-0.8440Analyst RevisionDRRXDURECT0.9762 of 5 stars$1.94+1.0%N/A+20.1%$59.62M$2.03M-19.4080Positive NewsDTILPrecision BioSciences3.953 of 5 stars$5.13+3.4%$47.00+816.2%-49.2%$58.46M$1.26M-0.58200IZTCInvizyne TechnologiesN/A$9.31flatN/AN/A$58.21MN/A0.0029News CoverageIMAImageneBio2.9271 of 5 stars$14.15-0.6%$35.50+150.9%-57.8%$57.20M$9.16M-1.8470News CoverageCLNNClene3.7124 of 5 stars$5.33-5.8%$33.00+519.1%-10.7%$56.55M$340K-1.42100News CoveragePDSBPDS Biotechnology2.6438 of 5 stars$1.30+9.2%$10.00+669.2%-59.5%$55.49MN/A-1.4120Gap UpHigh Trading VolumeICCCImmuCell0.6322 of 5 stars$6.09flatN/A+71.1%$55.12M$26.49M32.0570Positive News Related Companies and Tools Related Companies ANL Competitors IFRX Competitors HOWL Competitors DRRX Competitors DTIL Competitors IZTC Competitors IMA Competitors CLNN Competitors PDSB Competitors ICCC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts